Rezolute to Participate in the BTIG Virtual Biotechnology Conference
Rezolute (Nasdaq: RZLT), a late-stage biopharmaceutical company focused on developing novel therapies for rare diseases, has announced its participation in the BTIG Virtual Biotechnology Conference. The company's CEO and Founder, Nevan Charles Elam, will engage in a fireside chat on August 5, 2024, at 12:00 p.m. ET.
The Rezolute management team will also be available for one-on-one investor meetings throughout the conference. Interested investors are encouraged to contact their BTIG representative to schedule a meeting. This event provides an opportunity for Rezolute to showcase its progress in developing transformative therapies and engage with potential investors.
Rezolute (Nasdaq: RZLT), un'azienda biofarmaceutica in fase avanzata focalizzata sullo sviluppo di terapie innovative per malattie rare, ha annunciato la sua partecipazione alla BTIG Virtual Biotechnology Conference. Il CEO e Fondatore dell'azienda, Nevan Charles Elam, parteciperà a una conversazione informale il 5 agosto 2024, alle 12:00 ET.
Il team di gestione di Rezolute sarà inoltre disponibile per incontri individuali con gli investitori durante tutta la conferenza. Gli investitori interessati sono incoraggiati a contattare il proprio rappresentante BTIG per pianificare un incontro. Questo evento offre a Rezolute l'opportunità di mostrare i suoi progressi nello sviluppo di terapie trasformative e interagire con potenziali investitori.
Rezolute (Nasdaq: RZLT), una empresa biofarmacéutica en etapa avanzada centrada en el desarrollo de terapias novedosas para enfermedades raras, ha anunciado su participación en la BTIG Virtual Biotechnology Conference. El CEO y fundador de la empresa, Nevan Charles Elam, participará en una charla informal el 5 de agosto de 2024, a las 12:00 p.m. ET.
El equipo de dirección de Rezolute también estará disponible para reuniones individuales con inversores a lo largo de la conferencia. Se anima a los inversores interesados a contactar a su representante de BTIG para programar una reunión. Este evento ofrece a Rezolute la oportunidad de mostrar su progreso en el desarrollo de terapias transformadoras e interactuar con posibles inversores.
Rezolute (Nasdaq: RZLT)는 희귀 질환에 대한 새로운 치료법 개발에 집중하는 후기 단계의 생명공학 회사로, BTIG 가상 생명공학 회의에 참여한다고 발표했습니다. 회사의 CEO 겸 창립자인 Nevan Charles Elam은 2024년 8월 5일 오후 12:00 ET에 '파이어사이드 채팅'에 참여할 예정입니다.
Rezolute 경영진 팀은 또한 회의 전반에 걸쳐 개별 투자자 회의를 위해 대기할 것입니다. 관심 있는 투자자는 회의 일정을 잡기 위해 BTIG 대표에게 연락하도록 권장됩니다. 이 행사는 Rezolute에게 혁신적인 치료법 개발의 진행 상황을 발표하고 잠재 투자자와 소통할 수 있는 기회를 제공합니다.
Rezolute (Nasdaq: RZLT), une entreprise biopharmaceutique en phase avancée se consacrant au développement de nouvelles thérapies pour les maladies rares, a annoncé sa participation à la BTIG Virtual Biotechnology Conference. Le PDG et fondateur de l'entreprise, Nevan Charles Elam, participera à une discussion informelle le 5 août 2024 à 12h00 ET.
L'équipe de direction de Rezolute sera également disponible pour des réunions individuelles avec des investisseurs tout au long de la conférence. Les investisseurs intéressés sont encouragés à contacter leur représentant BTIG pour planifier une réunion. Cet événement offre à Rezolute l'occasion de mettre en avant ses progrès dans le développement de thérapies innovantes et d'interagir avec des investisseurs potentiels.
Rezolute (Nasdaq: RZLT), ein biopharmazeutisches Unternehmen in der späten Entwicklungsphase, das sich auf die Entwicklung neuartiger Therapien für seltene Krankheiten konzentriert, hat seine Teilnahme an der BTIG Virtual Biotechnology Conference bekannt gegeben. Der CEO und Gründer des Unternehmens, Nevan Charles Elam, wird am 5. August 2024 um 12:00 Uhr ET an einem Gespräch teilnehmen.
Das Management-Team von Rezolute wird während der gesamten Konferenz außerdem für eins-zu-eins-Treffen mit Investoren zur Verfügung stehen. Interessierte Investoren werden ermutigt, ihren BTIG-Vertreter zu kontaktieren, um ein Treffen zu vereinbaren. Diese Veranstaltung bietet Rezolute die Möglichkeit, seine Fortschritte bei der Entwicklung transformierender Therapien zu präsentieren und mit potenziellen Investoren in Kontakt zu treten.
- None.
- None.
REDWOOD CITY, Calif., July 31, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder of Rezolute, will participate in a fireside chat during the BTIG Virtual Biotechnology Conference on Monday, August 5, 2024, at 12:00 p.m. ET.
Management will be participating in one-on-one investor meetings throughout the conference. Investors interested in scheduling a meeting with the Rezolute management team should contact their BTIG representative.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, RZ358, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism (cHI) and tumor hyperinsulinism (tHI).
Contacts:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614
FAQ
When is Rezolute (RZLT) participating in the BTIG Virtual Biotechnology Conference?
Who will represent Rezolute (RZLT) at the BTIG Virtual Biotechnology Conference?
How can investors meet with Rezolute (RZLT) management during the BTIG conference?
What is the focus of Rezolute (RZLT) as a biopharmaceutical company?
